Trial Profile
Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 04 Feb 2024 Status changed from active, no longer recruiting to completed.
- 14 Mar 2023 Planned End Date changed from 8 Feb 2023 to 8 Dec 2023.
- 09 Mar 2022 Planned End Date changed from 8 Feb 2022 to 8 Feb 2023.